StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report sent to investors on Wednesday morning. The brokerage issued a hold rating on the stock.

Several other research firms also recently commented on EKSO. Lake Street Capital reduced their price objective on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Ekso Bionics in a report on Tuesday, March 4th.

Ekso Bionics Trading Up 11.1 %

NASDAQ:EKSO opened at $0.50 on Wednesday. The stock has a market cap of $12.41 million, a price-to-earnings ratio of -0.77 and a beta of 1.43. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. The company’s 50 day moving average price is $0.54 and its 200-day moving average price is $0.77. Ekso Bionics has a 52 week low of $0.34 and a 52 week high of $1.53.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.07). The business had revenue of $5.09 million for the quarter, compared to analysts’ expectations of $5.05 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. On average, equities research analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.